NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
Updated: Feb 5
CELMoD - CC-92480 - Mezigdomide - MEZI
NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Sponsor
Multiple locations
International Study
ClinicalTrials.gov Identifier: NCT05372354
Official Title: An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma
First Posted : May 12, 2022
Click here for details on ClinicalTrials.gov
cereblon E3 ubiquitin ligase modulating agent CC-92480
Mezigdomide (Code C146660)
CC 92480
CC-92480
CELMoD CC-92480
Cereblon E3 Ligase Modulation Drug CC-92480
Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480
Cereblon Modulator CC-92480
Mezigdomide
MEZIGDOMIDE
Drug: CC-92480
Drug: Tazemetostat
Drug: BMS-986158
Drug: Trametinib
Drug: Dexamethasone
Locations
United States, Alabama
United States, New York
Canada, Ontario
Europe
Norway
Spain
United Kingdom
RELATED POSTS
NCT05552976: Phase 3: (SUCCESSOR-2) CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM
NCT05519085: Phase 3: (SUCCESSOR-1) CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
Opmerkingen